EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

ADRB2 genotype‐guided treatment for childhood asthma: Cost analysis of the PUFFIN and PACT trials

E M A Slob, G W J Frederix, S J H Vijverberg iD, L C E Noij, T Ruffles iD, E C Vasbinder, S Mukhopadhyay, R H N van Schaik, E T G Kersten, M W Pijnenburg, G H Koppelman, A H Maitland-van der Zee und 1 weitere

Pediatric Allergy and Immunology · 2025

DOI: 10.1111/pai.70113 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Allergy and Immunology, 2025. Verfasst von E M A Slob und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Adrenergic beta-2 Receptor Agonists, Anti-Asthmatic Agents, Asthma, Receptors, Adrenergic, beta-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Henry Smith Charity, Action Medical Research, Lung Foundation Netherlands.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long‐acting β2‐agonists (LABA) are commonly used to treat asthma. Some children do not respond well to LABA, which may be due to +46G>A−/rs1042713 (Arg16 amino acid) in the ADRB2 gene encoding the β2 receptor. Arg16Gly ADRB2 genotyping to guide treatment step‐up decisions in children with uncontrolled asthma despite inhaled corticosteroids (ICS) has been shown to reduce asthma exacerbations. We investigated whether ADRB2 genotype‐guided treatment is cost‐saving.

Methods

Total semi‐annual healthcare and indirect costs for children with and without exacerbations were calculated using PUFFIN trial data. One hundred and two Dutch and Swiss children were randomised to a genotype‐guided treatment arm (adding LABA [Gly16Gly] or double dose ICS [Arg16Arg/Arg16Gly]) or a control arm, where children were again randomised to LABA or double dose ICS. We used exacerbation rates of the PUFFIN and the PACT trials to calculate asthma‐related healthcare costs per treatment arm, as PACT closely matches the PUFFIN design. The PACT trial randomised 91 children from England and Scotland with uncontrolled asthma to the genotype‐guided treatment arm (LABA [Gly16Gly] or montelukast [Arg16Arg/Arg16Gly]) or the control arm (routine care as per British Thoracic Society guidelines).

Results

Overall mean semi‐annual costs per child were €56.24 lower in the genotype‐guided treatment arm compared to the control arm (€771.07 [range €616.86–€925.28, 23 of 90 children experienced exacerbations] and €827.31 [range €661.85–€992.77, 40 of 103 experienced exacerbations], respectively).

Conclusion

A treatment strategy that includes ADRB2 genotype‐guided treatment is potentially cost‐saving compared to usual care. The decreased healthcare costs associated with a reduction in asthma exacerbations more than offset the incurred genotyping costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-2 Receptor AgonistsAnti-Asthmatic AgentsAsthmaReceptors, Adrenergic, beta-2AdolescentChildChild, PreschoolFemaleHumansMaleAdrenal Cortex HormonesGenotypeHealth Care CostsNetherlands

Stichwörter der Autor:innen

ADRB2beta2 receptorchildhood asthmacost analysispharmacogenetics

Substanzen

ADRB2 protein, humanAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAnti-Asthmatic AgentsReceptors, Adrenergic, beta-2

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Clinical Pharmacy, Diakonessenhuis, Utrecht, The Netherlands.
  • Department of Clinical Pharmacy, Haaglanden Medical Center, The Hague, The Netherlands.
  • Department of Public Health, Julius Center Research Program Methodology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, University of Brighton and University of Sussex, Brighton, UK.

ORCID-Profile: S J H Vijverberg, T Ruffles

Förderung

  • Henry Smith Charity
  • Action Medical Research
  • Lung Foundation Netherlands

Zitieren

APA

Slob, E. M. A., Frederix, G. W. J., Vijverberg, S. J. H., Noij, L. C. E., Ruffles, T., Vasbinder, E. C., Mukhopadhyay, S., van Schaik, R. H. N., Kersten, E. T. G., Pijnenburg, M. W., Koppelman, G. H., Maitland-van der Zee, A. H., & PUFFIN and PACT investigators (2025). ADRB2 genotype‐guided treatment for childhood asthma: Cost analysis of the PUFFIN and PACT trials. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70113

Vancouver

Slob EMA, Frederix GWJ, Vijverberg SJH, Noij LCE, Ruffles T, Vasbinder EC, et al. ADRB2 genotype‐guided treatment for childhood asthma: Cost analysis of the PUFFIN and PACT trials. Pediatric Allergy and Immunology. 2025. doi:10.1111/pai.70113

BibTeX
@article{Slob2025,
  author = {Slob, E M A and Frederix, G W J and Vijverberg, S J H and Noij, L C E and Ruffles, T and Vasbinder, E C and Mukhopadhyay, S and van Schaik, R H N and Kersten, E T G and Pijnenburg, M W and Koppelman, G H and Maitland-van der Zee, A H and PUFFIN and PACT investigators, PUFFIN and PACT investigators},
  title = {ADRB2 genotype‐guided treatment for childhood asthma: Cost analysis of the PUFFIN and PACT trials},
  journal = {Pediatric Allergy and Immunology},
  year = {2025},
  doi = {10.1111/pai.70113}
}
Kostenlos starten →